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Abstract
Background: Epigenetic control is essential for maintenance of tissue hierarchy and correct differentiation. In
cancer, this hierarchical structure is altered and epigenetic control deregulated, but the relationship between these
two phenomena is still unclear. CD133 is a marker for adult stem cells in various tissues and tumour types. Stem
cell specificity is maintained by tight regulation of CD133 expression at both transcriptional and post-translational
levels. In this study we investigated the role of epigenetic regulation of CD133 in epithelial differentiation and
cancer.
Methods: DNA methylation analysis of the CD133 promoter was done by pyrosequencing and methylation
specific PCR; qRT-PCR was used to measure CD133 expression and chromatin structure was determined by ChIP.
Cells were treated with DNA demethylating agents and HDAC inhibitors. All the experiments were carried out in
both cell lines and primary samples.
Results: We found that CD133 expression is repressed by DNA methylation in the majority of prostate epithelial
cell lines examined, where the promoter is heavily CpG hypermethylated, whereas in primary prostate cancer and
benign prostatic hyperplasia, low levels of DNA methylation, accompanied by low levels of mRNA, were found.
Moreover, differential methylation of CD133 was absent from both benign or malignant CD133+/a2b1integrinhi
prostate (stem) cells, when compared to CD133-/a2b1integrinhi (transit amplifying) cells or CD133-/a2b1integrinlow
(basal committed) cells, selected from primary epithelial cultures. Condensed chromatin was associated with CD133
downregulation in all of the cell lines, and treatment with HDAC inhibitors resulted in CD133 re-expression in both
cell lines and primary samples.
Conclusions: CD133 is tightly regulated by DNA methylation only in cell lines, where promoter methylation and
gene expression inversely correlate. This highlights the crucial choice of cell model systems when studying
epigenetic control in cancer biology and stem cell biology. Significantly, in both benign and malignant prostate
primary tissues, regulation of CD133 is independent of DNA methylation, but is under the dynamic control of
chromatin condensation. This indicates that CD133 expression is not altered in prostate cancer and it is consistent
with an important role for CD133 in the maintenance of the hierarchical cell differentiation patterns in cancer.
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Background
Epigenetic regulation of gene expression is a dynamic
mechanism, which permits precise regulation throughout
differentiation [1]. It plays a crucial role in preserving the
hierarchical structure of tissues and is involved in main-
taining stemness and fate determination of adult stem
cells [2,3]. Indeed, DNA methylation varies throughout
cell differentiation [4] and epigenetic control is required
for the multipotency of hematopoietic stem cells [5].
There is mounting evidence to support the hypothesis
that cancers can retain the hierarchical structure present
in normal tissues, but that homeostasis is disrupted,
leading to aberrant replication and differentiation. As in
normal tissues, a small percentage of cancer cells can
persist and initiate new tumour growth (tumour-initiat-
ing cells or cancer stem cells - CSCs), while most cells
proceed to terminal differentiation [6].
CD133 is a pentaspan membrane glycoprotein first
identified in humans as a hematopoietic stem cell mar-
ker [7] and is currently used for the identification of
stem cells from several tissues and cancer types [8]. In
non-malignant human prostate, CD133 and a2b1integrin
are two markers that, when used in combination, have
been demonstrated to enrich for a cell population with
stem cell features [9]. Indeed, CD133+ cells from human
primary tissues represent a very small subpopulation
(0.1-3.0% of the total prostatic epithelium) located in
the basal compartment. Tissue stem cells are restricted
to the a2b1integrin
hi population, have a high colony-
forming ability and proliferative potential, and are able
to regenerate fully differentiated prostate epithelium in
vivo. The stem cells express basal cell markers, such as
CD44 and CK5/14, but do not express luminal markers
AR, PSA or depend on androgens for their survival
[9-11]. Other markers have been used to identify pros-
tate stem cells, for example, in murine models, where
selection markers include Sca-1 [12] and CD117 [13].
CD133+ cells from prostate cancer biopsies (PCSCs)
are similar in phenotype to normal prostate stem cells.
They are rare (0.1-0.5% of the total cell population) and
represent the clonogenic population with highest prolif-
erative potential. Moreover, they express basal cell cyto-
keratins, but do not express AR [14].
Disruption of epigenetic mechanisms is found in all
cancers and, together with genetic changes, plays a key
role in cancer initiation and progression [15]. Epigenetic
studies in prostate cancer (CaP) have resulted in the
identification of hundreds of hypermethylated genes, of
which GSTP1 is the most studied [16], as well as
changes to chromatin structure and histone-modifying
enzymes [15].
However, these studies do not take into account the
hierarchical structure of cancer, since they describe
epigenetic alterations that occur in the bulk population
of cancer cells. It has been proposed that disruption of
epigenetic control may result in formation of aberrant
self-renewing cells [17], culminating in a complete
deregulation of the hierarchical system, ultimately lead-
ing to cancer [18]. Thus, understanding how epigenetic
regulation of gene expression controls the differentiation
process and its deregulation in cancer is of great impor-
tance in order to develop new therapeutic strategies for
cancer, directed to the therapy resistant cancer stem cell
population.
CD133 expression is controlled at multiple steps
including transcriptional regulation, alternative tran-
scription initiation sites, alternative splicing and post-
translational modifications [8,19]. This fine regulation
results in the maintenance of stem cell-specific CD133
expression patterns. Twelve different mRNA isoforms,
generated by alternative splicing, have been described in
various mammals (CD133.s1 - s12), of which at least
seven are expressed in human cells [19]. Moreover, five
different alternative first exons, regulated by five TATA-
less promoters, have been described [20] (Figure 1A).
Transcription is initiated from different first exons in a
tissue specific manner. In particular, only exon 1A is
expressed in prostate, indicative of promoter P1 activity.
The presence of a large CpG island in the CD133 pro-
moter area and the silencing of promoters P1 and P2
transcriptional activity by in vitro DNA methylation,
suggest that this gene can be regulated by epigenetic
mechanisms [20].
Here, we show that CD133 expression is efficiently
repressed by promoter methylation in prostate cell lines.
However, in primary cultured cells from prostate epithe-
lium and tumour xenografts, regulation of CD133
expression is independent of DNA methylation, indicat-
ing that, for this gene, cell lines are not indicative of
DNA methylation status in primary tissues. In addition,
the CD133 promoter is not hypermethylated in prostate
cancer tissues, highlighting the important role for
CD133 in the maintenance of the hierarchical structure
of cancer.
Results
The CD133 promoter region is hypermethylated in
prostate cancer cell lines
CD133 promoter methylation was quantified by pyrose-
quencing in prostate cell lines (Figure 1B, Additional
File 1, Figure S1B-C) using 3 assays (PYRO 1-3 assays)
located on promoter P1/exon 1A, promoter P2 and
exon 1C respectively (Figure 1A). Using the PYRO 1
assay, significant hypermethylation was found in the
majority of cell lines analysed, relative to the 0% methy-
lation control (0% Me) (p < 0.05), apart from the benign
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cell line RC-165N/hTERT and the cancer cell line P4E6
(Figure 1B). However, when each individual CpG site
was analysed separately, significant hypermethylation (p
< 0.05) was found at CpG sites 2-3-4 in P4E6 cells. Very
high levels of CD133 promoter methylation were found
in the CaP cell lines PC3 (70%), DU145 (80%), VCaP
(83%) and LnCaP (67%) (p < 0.001). The benign cell
lines BPH-1, PNT2 and PNT2-C2, also showed signifi-
cant hypermethylation (p < 0.001 - average methylation
between 30% and 50%). The CaP-derived Bob and Ser-
Bob cell lines showed a very heterogeneous pattern of
methylation throughout the sequence analysed, with
higher levels of methylation in SerBob (p < 0.01) than
Bob (p < 0.05). Significant, but low methylation levels (p
< 0.01) were found in the RC-92a/hTERT cancer cell
line.
To assess whether the levels of methylation were con-
sistent along the entire CpG island, PYRO 2 and 3
assays were carried out, and both showed comparable
patterns of methylation with the PYRO 1 assay (Addi-
tional File 1, Figure S1B-C). Finally, to confirm our find-
ings, a standard methylation-specific PCR (MSP) was
also carried out (Additional File 1, Figure S1A) and gave
results that matched with those obtained by
pyrosequencing.
The data summarised in Figure 1B implies that both
malignancy and culture conditions (presence of fetal calf
serum - FCS) influences the methylation status of the
CD133 CpG island. The cell lines analysed could be
divided into four groups, depending on the type of tis-
sue from which they were derived (benign or CaP) and
the amount of FCS present in the culture medium (≤
2% or >2%). A significant difference (p < 0.01) in aver-
age CD133 promoter methylation was found between
benign and cancer derived cell lines cultured in high
levels of FCS, but also between CaP cell lines cultured
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Figure 1 CD133 promoter is hypermethylated in prostate cancer cell lines. (A) The CD133 promoter (adapted from Shmelkov et al., 2004
[20]) (A,B,C,D1-3, E1-4 = alternative first exons; P1-P5 = promoters; Ex2 = Exon 2; ORF = open reading frame; PYRO 1-3: pyrosequencing assays;
MSP1-2: MSP assays; CHIP 1-8: ChIP primers). (B) Pyrosequencing analysis of the CD133 promoter performed in prostate cell lines (PYRO 1 assay;
bars = single CpG sites; n = 3 technical replicas; x¯ ± SD; black line = average of 10 CpG sites; * = p < 0.05; ** = p < 0.01; *** = p < 0.001 in an
unpaired t-test).
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in low or high levels of FCS (Additional File 1, Figure
S1D).
CD133 expression is regulated by DNA methylation in
prostate cell lines
In order to test whether CD133 expression was directly
regulated by DNA methylation, prostate cell lines were
treated with the demethylating agent 5-Aza-2’-deoxycy-
tidine (1 μM for 96 h). CD133 expression (measured by
qRT-PCR) was induced in 2 out of 4 benign cell lines
(BPH-1 and PNT1A) and all of the CaP cell lines ana-
lysed (P4E6, RC-92a, Bob, SerBob, PC3, DU145 and
LnCaP) with the exception of VCaP (Figure 2A). The
lack of induction in VCaP, could be explained by the
fact that this cell line has a doubling time of 5-6 days
[21], which is insufficient time for the 5-Aza-2’-deoxycy-
tidine to be incorporated into the genome during the 96
h treatment and to exploit its demethylating function.
Importantly, DNA demethylation did not induce CD133
expression in RC-165N/hTERT, confirming that CD133
is not repressed by DNA methylation in this cell line.
Next, 3 cell lines representative of the panel used were
treated with 1 μM 5-Aza-2’-deoxycytidine for 96 h and
analysed by FACs for the expression of the glycosylated
form of CD133 (Figure 2B and 2C). As expected, no sig-
nificant change in CD133 expression was seen in RC-
165n/hTERT after demethylation, while a significant
increase was seen in BPH-1 and marked increase
(although not significant) in LnCaP.
Taken together, these results show that DNA
demethylation induces CD133 upregulation, indicating
that promoter methylation suppresses CD133 expression
in prostate cell lines.
A direct comparison between CD133 expression, mea-
sured by qRT-PCR, and DNA methylation (PYRO 1
assay), confirmed that hypermethylation of the CD133
promoter results in downregulation of gene expression
(Figure 2D). Cell lines expressing high levels of mRNA
had the lowest levels of promoter methylation (e.g. RC-
165N/hTERT), while CD133 was strongly downregu-
lated when high levels of methylation were present (e.g.
VCaP and LnCaP). However, in cancer cells grown in
low levels of FCS, the CD133 promoter showed low
DNA methylation (less than 20%) associated with low,
but detectable expression (P4E6 and RC-92a/hTERT).
This confirmed that culture conditions influence DNA
methylation of the CD133 promoter and suggests that
other mechanisms, in addition to DNA methylation,
resulted in downregulation of CD133 expression.
Moreover, mRNA abundance and expression of the
glycosylated isoform of CD133 (detected by the 293C3
antibody) directly correlated in prostate cell lines (Addi-
tional File 2, Figure S2). All the benign cell lines (RC-
165N/hTERT, PNT1A, PNT2-C2, BPH-1) and 3 of the
cancer cell lines (Bob, P4E6 and RC-92a/hTERT), ana-
lysed for CD133 expression (by flow cytometry), con-
tained CD133+ cells and had detectable levels of
mRNA. In contrast, CD133+ cells were not found in
PC3 and DU145 cells, although detectable levels of
mRNA were found; while in LnCaP and VCaP cells,
CD133 was not detectable at either the mRNA or pro-
tein level. Finally, in SerBob cells, although CD133 was
undetectable at the mRNA level, we detected a very
small subpopulation of cells expressing very low levels
of CD133 protein.
Low levels of CD133 promoter methylation are found in
prostate tissues and primary epithelial cultures
CD133 expression (qRT-PCR - Figure 3A) and methyla-
tion of its promoter (PYRO 1 assay - Figure 3B-D) were
then measured in primary epithelial cultures derived
from clinical samples of benign prostatic hyperplasia
(BPH), CaP and castration resistant prostate cancer
(CR-CaP). Expression of CD133 was undetectable in 7
out of 10 samples, and detectable, but at low levels, in
the remaining 3. No differences in CD133 mRNA
expression were seen between BPH and CaP. These
results are in line with previous results showing that
CD133 is expressed (at the protein level) only in a small
subpopulation of the prostate primary epithelial cultures
[9,14,22,23]. DNA methylation levels were unexpectedly
low, with the average methylation less than 20%, in all
the samples analysed. No significant distinction was
seen between BPH, CaP or CR-CaP. In fact, only 2/6
BPH, 1/8 CaP and none of the CR-CaP samples con-
tained significantly hypermethylated DNA compared to
the 0%Me control. CaP 17 (Figure 3C) and CaP 28 (Fig-
ure 3D) clearly showed hypermethylation of a few CpG
sites, and separate analysis of each individual CpG site
revealed significant hypermethylation (p < 0.05) in CpG
site 10 for CaP 17 and sites 3 and 7 for CaP 28. The
results obtained were then confirmed by pyrosequencing
using the PYRO 2 assay (Additional File 3, Figure S3E)
and by MSP (Additional File 3, Figure S3A). The results
indicate that CD133 is not tightly regulated by DNA
methylation in prostate primary epithelial cells, which
was confirmed by a lack of a strong and consistent
increase in CD133 expression after treatment with 5-
Aza-2’-deoxycytidine (1 μM for 96 h - Not shown).
Lack of hypermethylation of the CD133 promoter in
CaP was then confirmed in CaP xenografts recently
established in RAG2-/- gamma C-/- immunocompro-
mised mice (Figure 4A). None of the samples showed
any significant hypermethylation of the CpG island,
although Xeno 30 showed hypermethylation of CpG
sites 3 and 4 (p < 0.05). Moreover, a small subpopula-
tion of CD133 positive cells, reminiscent of the stem-
like cells present in prostate cancer primary epithelial
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Figure 2 CD133 expression is repressed by DNA methylation in prostate cancer cell lines. (A) qRT-PCR analysis (relative to HPRT, calibrator
= P4E6) of CD133 expression in prostate cell lines treated with 1 μM 5-Aza-2’-deoxycytidine for 96 hours. (N.D. = expression undetectable after
40 cycles, n = 2; x¯ ± SD, * = p < 0.05; ** = p < 0.01 in a paired t-test, p-value not calculated in cell lines with non-detectable levels of CD133).
(B, C) FACs analysis of CD133 expression in prostate cell lines treated with 1 μM 5-Aza-2’-deoxycytidine for 96 hours. Live cells were stained with
CD133/2(293C)-APC antibody (Miltenyi Biotec) (CD133-APC) or without any antibody (No Antibody) and analysed by FACs. For each dot plot, X
axes: FITC channel fluorescence (not stained); Y axes: APC channel fluorescence (CD133 or No Antibody control); Percent of CD133+ cells is
indicated and the results are summarised in C. (D) Dot-plot showing expression (qRT-PCR, relative to HPRT, calibrator = Bob) and methylation of
CD133 in a panel of prostate cell lines grouped on the basis of their origin (benign or cancer) and their culture conditions (low FCS = 0%-2%;
high FCS = 5%-10%).
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Figure 3 CD133 expression and methylation in prostate primary epithelial cultures. (A) qRT-PCR analysis (relative to HPRT, calibrator =
Bob; N.D. = expression undetectable after 40 cycles) of CD133 expression in prostate primary epithelial cultures (RC-165N/hTERT and Bob were
used as controls). Methylation analysis of the CD133 promoter in prostate primary epithelial cultures derived from BPH (B), CaP (C) and CR-CaP
(D) by pyrosequencing (PYRO 1 assay; bars = single CpG sites; n = 3 technical replicas; x¯ ± SD; black line = average of 10 CpG sites; * = p <
0.05; ** = p < 0.01; *** = p < 0.001 in an unpaired t-test).
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Figure 4 Methylation of the CD133 promoter in prostate primary tissues and xenografts. Methylation analysis of the CD133 promoter in
primary prostate cancer xenografts generated in RAG2-/- gamma C-/- mice (A), in PC3 xenografts (D) and in prostate tissues (DNA extracted from
glass slides of pooled snap frozen tissue sections) (E) and by pyrosequencing (PYRO 1 assay; bars = single CpG sites; n = 3 technical replicas; x¯ ±
SD; black line = average of 10 CpG sites; * = p < 0.05; ** = p < 0.01; *** = p < 0.001 in an unpaired t-test). (B) Representative image of CD133
expression measured by FACs in disaggregated primary prostate cancer xenografts. X axes: FITC channel fluorescence (not stained); Y axes: APC
channel fluorescence (CD133-APC); Percent of CD133+ cells is indicated. (D) qRT-PCR analysis (relative to RPLP0, calibrator = PC3; N.D. =
expression undetectable after 40 cycles) of CD133 expression in PC3 xenografts compared to PC3 (RC-165N/hTERT was used as a positive
control).
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cultures [14], was present in these xenografts (Figure
4B).
To test whether the methylation of CD133 promoter
is a reversible event in vivo, CD133 mRNA expression
and promoter methylation was measured in xenografts
generated by subcutaneous injection of PC3 cells (Figure
4C and 4D). In both the samples tested, no significant
changes in expression or methylation of CD133 were
found when comparing PC3 cells in vitro and in vivo.
These results suggest that, once established, methylation
patterns within CD133 promoter are stable and not
easily reversible.
Lastly, these results were also confirmed by methyla-
tion analysis of the CD133 promoter in snap frozen
prostate tissues from both benign and CaP samples (Fig-
ure 4E, Additional File 3, Figure S3C-D). 2/4 BPH sam-
ples and 2/4 CaP samples showed significantly elevated,
but still very low levels (7% - 16%) of hypermethylation
(p < 0.05).
CD133 expression is not regulated by DNA methylation in
the prostate epithelial hierarchy
CD133 expression was next analysed by qRT-PCR in SC
(a2b1
hi/CD133+), TA (a2b1
hi/CD133-) and CB (a2b1
low/
CD133-) cell populations isolated from low passage
(<10) primary prostate epithelial cultures (1 BPH and 2
CaP) (Figure 5A). In BPH 09 and CaP 17, CD133
expression was undetectable in unselected cultures, CB
cells and TA cells, but was detectable (at low levels) in
SCs. CD133 expression was not detectable, in any sub-
population, from culture CaP 18. These results provided
evidence that CD133 can be regulated at the transcrip-
tional level during differentiation of prostate epithelia
from tissues.
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Figure 5 CD133 expression and methylation in prostate hierarchy. (A) qRT-PCR analysis of CD133 expression (relative to RPLP0, calibrator
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We then wanted to analyse whether this differential
regulation was sustained by DNA methylation. Pyrose-
quencing (PYRO 1 assay - Figure 5B) and MSP (Addi-
tional File 3, Figure S3B) were carried out on SC, TA
and CB cells. Low levels of methylation (<20%) were
found in all the populations. No significant differences
were found between the 3 populations analysed.
Chromatin structure, together with DNA
hypermethylation, lead to CD133 downregulation in
prostate epithelial cells
The presence of active (as detected by dimethylation
of lysine 4 of histone H3 - H3K4me2) or inactive (tri-
methylation of lysine 27 of histone H3 - H3K27me3)
chromatin around the CD133 promoter was deter-
mined by chromatin immunoprecipitation (ChIP) in
RC-165N/hTERT, PNT2-C2, P4E6 and PC3 cells (Fig-
ure 6A). H3K4 dimethylation was detected in the
CD133 promoter of RC-165N/hTERT cells, in accor-
dance with the transcriptional activity. The inactive
chromatin mark H3K27me3 was overrepresented in
P4E6 cells, indicating that chromatin structure, rather
than DNA methylation, played a more crucial role in
repressing CD133 expression in this cell line. PC3
cells also showed an inactive state of chromatin, with
tri-methylation of H3K27 and no enrichment for
H3K4me2. PNT2-C2 showed an intermediate state of
chromatin condensation where both markers for
active and inactive chromatin were present, matching
both the intermediate levels of methylation (around
40%) and gene expression (Figure 2A). Taken
together, these data indicated that changes in chro-
matin structure alone, or in co-operation with DNA
methylation, could result in the repression of CD133
expression.
P4E6 cells showed a very similar expression and DNA
methylation pattern to primary epithelial cultures and
primary tissues, containing low levels of CD133 mRNA
and promoter methylation. In this cell line CD133 was
maintained in a repressed state by a highly condensed
chromatin structure. In line with these results, CD133
mRNA was highly overexpressed after treatment of
P4E6 cells with trichostatin A (TSA, 0.6 μM for 24 and
48 hours) (Figure 6B), a well characterised histone dea-
cetylase (HDAC) inhibitor that relaxes chromatin by
inducing acetylation of histones.
Treatment of BPH and CaP derived primary epithelial
cultures with 0.6 μM TSA and 10 mM NaBu (a less
potent and specific HDAC inhibitor) also resulted in
overexpression of CD133 mRNA (Figure 6C-D) after 48
hours, in agreement with a clear role for condensed
chromatin structure in maintaining CD133 repression in
both cell lines and primary samples.
Discussion
CD133 is widely used as a marker for CSCs in many dif-
ferent solid tumours including: colon [24,25], brain
[26,27], skin [28], pancreatic [29], liver [30,31], and
prostate [14]. In both normal and cancerous prostate,
the expression of CD133 is restricted to a very small
subpopulation of cells with stem-like features, suggesting
a tight regulation for the expression of this gene
[9,14,32].
The data presented here indicated that DNA methyla-
tion mediated suppression of CD133 expression in pros-
tate epithelial cell lines, where an inverse correlation
between expression and DNA methylation was clearly
seen, together with re-expression of both the mRNA
and the glycosylated protein after gene demethylation by
5-Aza-2’-deoxycytidine treatment.
However, data obtained from prostate tissue and pri-
mary epithelial cultures displayed a stark contrast to
that obtained in cell lines. A huge variation (spanning
nearly 100,000 fold) in CD133 expression was found
across the cell lines analysed, while CD133 was unde-
tectable or expressed at very low levels in prostate pri-
mary epithelial cultures. These results provide strong
evidence that regulation of CD133 expression can be
disrupted during long-term culture in vitro.
Moreover, the low levels of CD133 mRNA detected in
primary epithelial cultures suggested that the CD133
gene was repressed in the vast majority of prostate basal
epithelial cells (with the exception of the stem cell
population). The very low levels of promoter methyla-
tion found in these samples indicated that repression of
CD133 expression was independent of promoter methy-
lation and implied that other mechanisms were required
to control CD133 expression in prostate tissues and pri-
mary cultures. Interestingly, CD133 expression was also
not deregulated in primary prostate cancer, suggesting
that a tight regulation of CD133 expression was impor-
tant in the hierarchical structure of both normal and
cancerous prostate.
Prostate epithelium is heterogeneous and composed of
various cell populations at different differentiation
stages. When SC (CD133+), TA and CB (CD133-) cell
populations from primary epithelial cultures were ana-
lysed separately, the results obtained showed no differ-
ential methylation of the CD133 promoter in individual
populations. Therefore mechanisms other than DNA
methylation must regulate CD133 expression in the
prostate epithelial cell hierarchy.
Our results indicated that one such mechanism is
chromatin condensation. In prostate cell lines, a con-
densed status correlated with low levels of mRNA (PC3
and P4E6 cells). This is in line with the concept of
crosstalk between different epigenetic mechanisms [33]
Pellacani et al. Molecular Cancer 2011, 10:94
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Figure 6 CD133 expression is regulated by chromatin structure in prostate cell lines and primary epithelial cultures. (A) ChIP-qPCR
analysis carried out in RC-165N/hTERT, PNT2-C2, P4E6, PC3 with rabbit IgG, anti-histone H3, anti-H3K4me2, and anti-H3K27me3. qPCR primer
positions are shown in Figure 1A (X axes: CD133 promoter sequence, 0 = 5’end of exon 1A; Y axes: percentage of immunoprecipitated DNA
relative to input DNA; n = 3; x¯ ± SD, data shown on logarithmic scale). (B) qRT-PCR analysis of CD133 expression in P4E6 cells lines with 0.6 μM
TSA for 24 and 48 hours (relative to HPRT, calibrator = Control, x¯ ± SD). (C,D) qRT-PCR analysis of CD133 expression in prostate primary epithelial
cultures (PEc) treated with 0.6 μM TSA (C) or 10 mM NaBu (D) for 48 hours (relative to HPRT, calibrator = Control, x¯ ± SD, data shown on
logarithmic scale).
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and with previous findings in glioblastoma and colon
cancer cell lines [34] where CD133 was regulated by
both DNA methylation and histone modifications. Inter-
estingly, chromatin structure seemed not only to parallel
DNA methylation in repressing CD133 expression, but
also to have an active role in repressing transcription
even when hypermethylation was not present (P4E6
cells). The same mechanism was also present in primary
epithelial cultures from both BPH and CaP, clearly indi-
cating an important role for chromatin structure in
repressing CD133 expression in primary prostate.
In prostate tissues, the glyscosylated form of CD133
was expressed only in a very small subpopulation of
basal epithelial cells [9,35]. However, it has recently
been shown that an isoform of CD133 protein that does
not have the same glycosylation pattern is present in
terminally differentiated prostate luminal cells [35]. So,
it is clear that the CD133 gene needs to be dynamically
regulated throughout differentiation of prostate epithe-
lia, clearly supporting the hypothesis that long-term
transcriptional silencing caused by DNA methylation is
unlikely to affect CD133 expression in prostate epithelia.
This also supports our findings that more dynamic
mechanisms, such as changes in histone modifications
and chromatin structure are the more likely control
mechanisms.
Although CD133 is widely used as a stem cell marker
in various types of cancer, very little is known about its
molecular function and its functional involvement in
tumour and metastasis formation. Even if there is evi-
dence that CD133- positive cells from various cancers
are more resistant to anti-cancer therapies [36-38], it is
not known whether CD133 has a primary role in this
resistance or it just happens to mark resistant cells.
Indeed CD133 has been shown to be involved in main-
taining neuroblastoma cells in an undifferentiated state,
and downregulation of CD133 led to inhibition of
tumour formation [39]. However, the wide expression of
this surface marker in various human tissues [40] and
the sparse knowledge of its molecular function pose
great difficulties in using CD133 as a target for cancer
stem cell therapy.
The results obtained show two different mechanisms
for regulation of CD133 expression in cell lines (DNA
methylation dependent) and primary tissues and
recently established prostate cancer xenografts (DNA
methylation independent). Although discrepancies
between cell lines and primary samples have been dis-
cussed in the literature for at least 20 years [41], cell
lines remain the most frequently used model for epige-
netics and cancer epigenetics studies; in many cases
with weak correlations to the original tissue/cancer. It
is known that de novo methylation is a common event
during cell line establishment [42,43] as part of the
adaptation process that cells undergo during long-term
culture. This process results in downregulation of
genes that are nonessential in culture, including many
tissue-specific genes [41]. The results presented here
for the expression of CD133, a common stem cell mar-
ker in multiple tissues, emphasise that cell lines do not
represent a valid model for DNA methylation studies,
since culture conditions influence promoter
methylation.
Thus, the choice of the correct cell model system is of
paramount importance when studying epigenetic regula-
tion of gene expression in cancer biology and stem cell
biology. The results with CD133 highlight the need for
verification (using primary tissues) of the results
obtained with cell lines. For example, in the last few
years, several high-throughput epigenetic studies com-
pared commercially available normal epithelial cultures
(non immortalised and cultured for a limited number of
passages) with established cancer cell lines in prostate
[44,45] and other tissues. In these comparisons, epige-
netic adaptation of cell lines to culture conditions was
not taken into account and the results obtained might
be biased by in vitro adaptation.
Finally, in recent studies designed to isolate cells with
stem cell features from prostate cancer cell lines a great
discordance was reported regarding the expression of
CD133 on the surface of several CaP cell lines. The data
presented here, reveal the limitations of the use of cell
lines in such studies, and indicate that prolonged in
vitro culture affects the fine gene regulation that is
essential for the maintenance of prostate epithelial hier-
archy. Moreover, the data presented by Pfeiffer and
Schalken (2010) [46], is in accordance with our data,
confirming the lack of cell surface expression of CD133
in many established prostate cancer cell lines, and when
expressed, CD133 did not appear to select for cells with
stem cell characteristics. Our results now provide a
mechanistic explanation for the apparently contrasting
results presented in that study.
Conclusions
We present here a comprehensive study of the epige-
netic regulation of CD133 promoter in cell lines, pri-
mary epithelial cultures, tissue and tumour xenografts
from the human prostate. We conclude that CD133
expression is regulated by different mechanisms in cell
lines relative to the other samples, and that regulation
in primary cultures is independent of methylation,
where this gene is maintained in a repressed state by
condensed chromatin structure. These results also have
implications in the choice of models that are chosen to
analyse epigenetic changes in cancer cells, and highlight
the complexity of regulation of this common stem cell
marker.
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Materials and methods
Cell lines, tissue processing, primary epithelial cell culture
and xenografts
A list of the cell lines used, origin, culture conditions
and identification is provided in Additional File 4, Table
S1.
Human prostatic tissue was obtained from patients
undergoing transurethral and retropubic prostatect-
omy for BPH or undergoing radical prostatectomy for
CaP (with patient consent and full ethical permission
from York District Hospital and Castlehill Hospital,
Hull). BPH or CaP diagnosis was confirmed by histo-
logical examination of representative adjacent
fragments.
Tissues were disaggregated and cultured as described
previously [9,10]. Basal cells were then cultured and
further fractionated on the basis of adhesion to type I
collagen [10]. CD133+ cells were selected from cells that
adhered within 20 minutes using MACS microbeads
linked to anti-human CD133, according to the manufac-
turer’s instruction (Miltenyi Biotec) [14].
Xenografts were generated by subcutaneous grafting of
CaP tissue in RAG2-/- gamma C-/- mice. Tumours gen-
erated were serially passaged in vivo and routinely geno-
typed to confirm the original patient’s genotype. Early
passages (1-3) were used for DNA methylation studies.
PC3 xenografts were generated by injecting subcuta-
neously 106 PC3 cells embedded in 100 μl of Matrigel
(BD Biosciences) in Balb/c Nude mice. Tumours were
harvested after 29 days from the injection.
DNA purification and sodium bisulfite conversion
DNA was extracted using the DNeasy Blood & Tissue
Kit (Qiagen) and the QIAamp DNA micro Kit (Qiagen)
for small samples. 0% and 100% methylated controls
were purchased from Qiagen (EpiTect PCR Control
DNA). 50 ng/1 μg of DNA was bisulfite converted using
the EpiTect Bisulfite Kit (Qiagen). Converted DNA from
SCs was amplified using the EpiTect Whole Bisulfitome
Amplification Kit (Qiagen).
Pyrosequencing assay
The CD133 promoter sequences were amplified by PCR
using specific primers for 3 regions of the CpG island
(Additional File 5, Table S2 and Figure 1A) and
sequenced using the PyroMark Q24 System (Qiagen).
Data were analysed with PyroMark Q24 software. In pri-
mary epithelial cultures and xenografts, a mixture of
human and mouse DNA was analysed. PYRO 1 (Addi-
tional File 6, Figure S4) and PYRO 2 (not shown) assays
were human specific. PYRO 3 gave non-specific PCR
products with mouse DNA (not shown) so it was not
used for mixed (human/mouse) samples.
Methylation-specific PCR
Methylation-specific PCR was carried out as previously
described [47] in a final 25 μL reaction mixture using
10 ng of bisulfite converted DNA as template and Plati-
num Taq DNA Polymerase (Invitrogen). Primer
sequences are listed in Supplementary Table 2. The
PCR program was: 94°C for 2 minutes, then 35 cycles of
94°C for 20 seconds, 55°C for 20 seconds, and 72°C for
20 seconds, with a final extension of 5 minutes at 72°C.
PCR products were separated by electrophoresis through
a 2% agarose GelRed (Invitrogen) stained gel for 1 h at
80 V and then visualized using a Gene Genius bio-ima-
ging system.
RNA extraction, cDNA synthesis and qRT-PCR
RNA was extracted using the RNeasy kit (Qiagen) and
reverse transcribed using random hexamers and reverse
transcriptase (Superscript III, Invitrogen). Real time PCR
was carried out using either Power mix SYBR Green and
specific primers (Additional File 5, Table S2) or TaqMan
gene expression pre-synthesized reagents and master mix
(CD133: Hs01009257_m1 and RPLP0: Hs99999902_m1,
Applied Biosystems). Reaction volumes were reduced to
25 μl for SYBR Green and 10 μl for TaqMan, and were
carried out as previously described [22]. Gene expression
was considered undetectable if fewer than 2/3 reactions
were positive after 40 cycles of PCR.
Flow Cytometry
Live cells were stained with CD133/2(293C)-APC anti-
body (1:11) (Miltenyi Biotec) and analysed on a CyAn
ADP flow cytometer (Dako Cytomation, Denmark).
Doublet cells were gated out with pulse width. Dead
cells were gated out by DAPI exclusion. More than
250,000 events were analysed.
Chromatin Immunoprecipitation
ChIP assays were performed as previously described
[48]. The antibodies histone H3 (Abcam), rabbit IgG,
H3K4me2, and H3K27me3 (Millipore) were used at a
1:100 dilution to immunoprecipitate an equivalent 20 μg
of DNA in ChIP assay. To standardize between experi-
ments, the percentage of immunoprecipitation (IP) was
calculated by dividing the value of the IP by the value of
the corresponding input (both values normalized for
dilution factors).
Additional material
Additional file 1: Additional analysis of CD133 promoter
methylation in prostate cell lines.Additional analysis of CD133
promoter methylation in prostate cell lines. Figure S1: Methylation
specific PCR (MSP) analysis of the CD133 promoter with two different
primer sets (MSP1 and MSP2) in a panel of prostate cell lines (A). PCR
products recognizing methylated (M) and unmethylated (U) CpG sites
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were analyzed on 2% agarose gels (Positive Control = RC165 DNA
methylated in vitro with SssI methylase; Negative Control = water).
Pyrosequencing methylation assay of CD133 CpG island in a panel of
prostate cell lines (panel B: PYRO 2 assay; panel C: PYRO 3 assay; each
bar represents a single CpG site; n = 3 technical replicas; x¯ ± SD; 100%
Meth = Methylated human control DNA - QIAGEN; 0% Meth =
Unmethylated human control DNA - QIAGEN; 50% Meth = 1:1 mixture of
100% Meth and 0% Meth). (D) Dot-plot showing CD133 promoter
methylation (PYRO 1 assay, average of 10 CpG sites) in the same cell
lines shown in Figure 1B grouped on the basis of their origin (benign or
cancer) and their culture conditions (low FCS = 0%-2%; high FCS = 5%-
10%; * = p < 0.05; ** = p < 0.01; *** = p < 0.001 in an unpaired t-test).
Additional file 2: Figure S2: Quantification of expression of the
stem cell marker CD133 in prostate cell lines. Live cells were stained
with CD133/2(293C)-APC antibody (Miltenyi Biotec) (CD133-APC) or
without any antibody (No Antibody) and analysed by FACs. For each dot
plot, X axes: FITC channel fluorescence (not stained); Y axes: APC channel
fluorescence (CD133 or No Antibody control); Percent of CD133+ cells is
indicated.
Additional file 3: Additional analysis of CD133 promoter
methylation in prostate primary epithelial cultures and prostate
tissues.Additional analysis of CD133 promoter methylation in
prostate primary epithelial cultures and prostate tissues. Figure S3:
MSP analysis of the CD133 promoter with two different primer sets
(MSP1 and MSP2) in prostate primary epithelial cultures (A) and in
selected populations from primary epithelial cultures (B) (SC = stem cells;
TA = transit amplifying cells; CB = committed basal cells; Negative
Control = water; NO CELLS = negative control for whole bisulfitome
amplification). Pyrosequencing methylation assay of CD133 promoter in
prostate tissues (panel C: PYRO 2 assay; panel D: PYRO 3 assay; DNA
extracted from glass slides of snap frozen tissue sections which were
pooled together) and in prostate primary epithelial cultures (panel E:
PYRO 2 assay; each bar represent a single CpG site; n = 3 technical
replicas; x¯ ± SD).
Additional file 4: Table S1: List of the cell lines used. Table indicating
the cell lines used in this manuscript, their origin and culture conditions.
Additional file 5: Table S2: List of the primers used Table indicating
the primers used in this manuscript for PCR amplification and
pyrosequencing.
Additional file 6: DNA methylation analysis of CD133 promoter
using pyrosequencing.DNA methylation analysis of CD133
promoter using pyrosequencing. Figure S4: (A) Diagram depicting a
typical histogram generated by pyrosequencing methylation analysis of
CD133 promoter with PYRO 1 assay and the position of each CpG site
on the genomic sequence (Exon 1 A is shown in yellow). (B-C) Example
of typical pyrograms generated with PYRO 1 assay using human (B) or
mouse (C) bisulfite converted DNA as a template for PCR. No PCR
product or sequence was generated with mouse DNA
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